Introduction

Gestational Diabetes Mellitus (GDM) affects approximately 6% to 9% of pregnancies in the United States, with rates varying by population and diagnostic criteria. It is defined as glucose intolerance that first appears or is detected during pregnancy, and it poses risks to both mother and baby if left untreated. Early detection through reliable screening is critical for initiating interventions that improve outcomes—including dietary changes, blood glucose monitoring, and, when necessary, medication. The choice of screening test matters because different tests offer varying levels of sensitivity, convenience, and diagnostic precision. This article examines the two primary screening methods, the factors that influence test selection, and the broader context of GDM diagnosis and management.

Common GDM Screening Tests

Two principal tests are used to screen for GDM: the Glucose Challenge Test (GCT) and the Oral Glucose Tolerance Test (OGTT). Many clinicians use a two-step approach—starting with the GCT—while others, especially in high-risk populations, may proceed directly to the more comprehensive OGTT. Understanding how each test works, when it is used, and what the results mean is essential for making an informed decision.

Glucose Challenge Test (GCT)

The GCT is a non-fasting screening test designed to identify women who are likely to have GDM and require further testing. During the test, the patient drinks a solution containing 50 grams of glucose. Blood is drawn one hour later to measure the plasma glucose level. A result equal to or above a predefined threshold—commonly 130 or 140 mg/dL—indicates a positive screen, prompting the need for a diagnostic OGTT.

Advantages of the GCT: The test is quick, requires no fasting, and can be performed at any time of day. Its simplicity makes it a practical first step for low-risk women. Because it uses a lower glucose load than the OGTT, it is generally well tolerated, with fewer reports of nausea or vomiting. The GCT also has a lower cost and imposes less time burden on the patient.

Limitations of the GCT: The GCT is a screening test, not a diagnostic one. A positive result does not confirm GDM; it merely indicates a higher probability. False positives can occur, leading to unnecessary follow-up testing and anxiety. Conversely, false negatives are possible, particularly if the threshold is set too high. The sensitivity of the GCT ranges from 70% to 85%, depending on the cutoff used and the population studied. Some guidelines recommend using the lower cutoff of 130 mg/dL to increase sensitivity, at the cost of more false positives.

GCT Procedure Tips: Women are usually advised to eat a normal meal before the test, although some practitioners prefer a light snack. It is important to avoid large amounts of sugar or caffeine in the hours before the test, as these could affect the result. After drinking the glucose solution, the patient should remain seated and not eat or drink anything until the blood draw is complete.

Oral Glucose Tolerance Test (OGTT)

The OGTT is the gold standard for diagnosing GDM. It is typically performed following an abnormal GCT, or as a first-line test in women with significant risk factors. The test requires an overnight fast of at least 8 hours. A fasting blood sample is taken, then the patient drinks a solution containing 75 grams of glucose (some protocols use 100 grams). Blood samples are collected at fasting, one hour, and two hours after ingestion (and sometimes at three hours if using the 100-gram protocol).

Diagnostic Criteria: The interpretation of OGTT results depends on the guidelines used. The most widely accepted criteria come from the International Association of Diabetes and Pregnancy Study Groups (IADPSG), which recommends the 75-gram, 2-hour test. GDM is diagnosed if any one of the following thresholds is met or exceeded: fasting ≥ 92 mg/dL, 1-hour ≥ 180 mg/dL, or 2-hour ≥ 153 mg/dL. Alternatively, the Carpenter-Coustan criteria—often used in the two-step approach—require two or more abnormal values on a 100-gram, 3-hour test: fasting ≥ 95, 1-hour ≥ 180, 2-hour ≥ 155, 3-hour ≥ 140 mg/dL. The choice of criteria can significantly affect the prevalence of GDM and the number of women classified as having the condition.

Advantages of the OGTT: The OGTT provides a comprehensive picture of glucose metabolism, capturing the fasting state and the body’s response to a glucose load over time. It has high sensitivity and specificity—approaching 90% or higher—when performed correctly. A single abnormal OGTT is sufficient to diagnose GDM under the IADPSG criteria, allowing for earlier and more uniform detection.

Limitations of the OGTT: The test is time-consuming (2–3 hours), requires fasting, and is more expensive than the GCT. Some women experience nausea, vomiting, or dizziness due to the high glucose load. If vomiting occurs shortly after drinking the solution, the test may need to be rescheduled. The OGTT also imposes a logistical burden, as women must remain in the laboratory or clinic for the duration of the test.

Risk Factors for GDM

Identifying risk factors helps clinicians decide which screening approach to use. Women with one or more of the following characteristics are considered high risk and may benefit from earlier or more comprehensive testing:

  • Maternal age over 25 years: The risk of GDM rises with age, especially after 35.
  • Overweight or obesity: A body mass index (BMI) ≥ 25 kg/m² (or ≥ 23 in Asian populations) is strongly associated with GDM.
  • Family history of diabetes: A first-degree relative (parent or sibling) with type 2 diabetes increases the risk.
  • Previous GDM: A history of GDM in a prior pregnancy confers a 30–50% recurrence risk.
  • Previous delivery of a large baby: An infant weighing ≥ 9 pounds (4,000 grams) suggests possible undiagnosed GDM.
  • Polycystic ovary syndrome (PCOS): Insulin resistance associated with PCOS elevates GDM risk.
  • Certain ethnicities: Higher rates are observed in Hispanic, African American, Native American, South Asian, and Pacific Islander populations.
  • Other conditions: Chronic hypertension, use of corticosteroids, or prior history of impaired glucose tolerance.

Women with no risk factors are considered low risk, though universal screening is still widely recommended because up to 50% of GDM cases occur in women without obvious risk factors.

When Should You Be Screened?

Screening timing depends on the level of risk. The standard approach endorsed by organizations such as the American College of Obstetricians and Gynecologists (ACOG) and the U.S. Preventive Services Task Force (USPSTF) is to perform screening at 24 to 28 weeks of gestation for all pregnant women. This timing aligns with the period when placental hormones begin to cause insulin resistance, typically unmasking GDM.

Early screening (first trimester or early second trimester): Women with strong risk factors (e.g., previous GDM, BMI ≥ 30, known impaired glucose tolerance) may undergo early screening at the first prenatal visit. If the initial screening is negative, it is repeated at 24–28 weeks. Early diagnosis allows for prompt management and may reduce the risk of complications such as macrosomia and preeclampsia. However, screening before 24 weeks is not recommended for average-risk women because of lower accuracy and lack of proven benefit.

Late screening: Some women who develop symptoms of hyperglycemia later in pregnancy (e.g., excessive fetal growth, polyhydramnios) may be screened again after 28 weeks. In general, adherence to the 24–28 week window captures the vast majority of cases.

Choosing Between GCT and OGTT

The decision to start with a GCT or proceed directly to an OGTT balances factors such as convenience, accuracy, cost, and individual risk profile. The two-step approach (GCT followed by OGTT if positive) remains the most common in the United States, while the one-step approach (direct OGTT at 24–28 weeks) is preferred in many other countries and by organizations like the International Federation of Gynecology and Obstetrics (FIGO).

When the GCT is a good first choice:

  • You have no major risk factors.
  • You want a quick, non-fasting test.
  • Your healthcare provider follows ACOG’s two-step protocol.
  • You have a history of tolerating the test well in previous pregnancies.

When the OGTT may be preferred as a starting test:

  • You have one or more significant risk factors (especially obesity, family history, or PCOS).
  • You had GDM in a previous pregnancy.
  • You prefer a single diagnostic test to avoid potential follow-up visits.
  • Your provider uses the IADPSG/one-step criteria.
  • You are participating in a research protocol that uses uniform diagnostic standards.

Comparative accuracy: A positive GCT at a cutoff of 130 mg/dL catches about 80–90% of GDM cases, but many positive screens will be false alarms. The OGTT, particularly with IADPSG criteria, has a false positive rate of less than 5% and higher specificity. In a systematic review published in BMJ Open, the two-step approach was associated with a lower diagnosis rate than the one-step approach, leading to debate about which strategy is optimal for maternal and neonatal outcomes.

Cost and convenience: The GCT is less expensive (typically $30–$60) compared to the OGTT ($100–$200 or more). The OGTT requires a longer time commitment and fasting, which may be challenging for women with morning sickness or demanding schedules. Some women prefer the GCT because it causes less disruption, even though it may require a second visit if positive.

Ultimately, the “right” test is the one that aligns with your specific risk profile, your healthcare system’s protocols, and your personal preferences—discussed thoroughly with your obstetric provider. No single test is perfect; what matters most is that screening occurs and that abnormal results are followed up in a timely manner.

After an Abnormal Screening: Next Steps

If your GCT result is elevated, you will be scheduled for a diagnostic OGTT. It is important not to panic—most women with a positive GCT do not have GDM. In a typical low-risk population, only about 15–20% of positive GCTs confirm GDM on OGTT. However, because untreated GDM can lead to serious complications, follow-up is essential.

Management of diagnosed GDM:

  • Lifestyle modifications: Dietary changes (spacing meals, reducing simple carbohydrates, increasing fiber) and moderate physical activity (e.g., 30 minutes of walking most days) are first-line interventions. Blood glucose monitoring (fasting and postprandial) is taught and typically performed four times daily.
  • Medication: If lifestyle measures fail to maintain glucose targets, insulin is the preferred treatment in pregnancy. Oral agents like metformin and glyburide are used in some settings, though they cross the placenta and have varying safety profiles.
  • Fetal monitoring: Increased surveillance—including ultrasound for fetal growth and amniotic fluid volume—may be recommended, especially if GDM is poorly controlled or if the mother requires medication.
  • Postpartum follow-up: Women with GDM have a 35–60% risk of developing type 2 diabetes within 10 years. A 75-gram OGTT is recommended at 4–12 weeks postpartum, with continued screening every 1–3 years thereafter.

Beyond the Basics: Emerging Screening Approaches

While the GCT and OGTT remain the standard of care, researchers continue to explore alternative methods. Hemoglobin A1c (HbA1c) is not recommended for diagnosing GDM due to pregnancy-induced changes in red blood cell turnover, but it may help identify women with pre-existing diabetes. Continuous glucose monitoring (CGM) has been studied as a screening tool, but it is not yet validated for diagnosis and is more expensive. Fasting plasma glucose alone has poor sensitivity for GDM and is not used for screening. The development of risk-prediction models incorporating maternal characteristics may eventually allow more targeted screening, but for now, the glucose-based tests remain the most evidence-based methods.

External resources for further reading:

Conclusion

Selecting the right GDM screening test is a shared decision between you and your healthcare provider, based on your personal risk profile, the timing of your pregnancy, and the established protocols in your practice. The Glucose Challenge Test offers convenience and is a reasonable starting point for most low-risk women, while the Oral Glucose Tolerance Test provides more definitive diagnostic information and is indicated for those at higher risk or after a positive screen. Regardless of which test is chosen, the goal remains the same: early identification of GDM so that effective management can be initiated, reducing the risk of adverse outcomes for both mother and baby. Stay informed, ask questions, and work closely with your care team to ensure the best possible pregnancy journey.